Beigene Ltd

NASDAQ:BGNEUnited States

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Contact Information

Headquarters

C/O Mourant Governance Services (Cayman) 94 Solaris Avenue, Camana BayGRAND CAYMAN, BEJ, Cayman Islands KY1-1108

Phone

345-949-4123

Fax

---

Executives

Co-Founder, Executive Chairman of the Board, Chief Executive Officer

John Oyler

President, Chief Operating Officer, General Manager - China

Xiaobin Wu

Co-Founder, Non-Executive Director

Xiaodong Wang

Chief Financial Officer

Aaron Rosenberg

Senior Vice President, General Counsel

Chan Lee